Friday, 6 November 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 2, 2026

T-Mobile Pairs iPhone 17e and iPad Air with Plans that Bring Built-in Value from Day One

View original at finance.yahoo.com
T-Mobile Pairs iPhone 17e and iPad Air with Plans that Bring Built-in Value from Day One T-Mobile, Metro by T-Mobile and UScellular will offer the new iPhone 17e, which delivers incredible value with faster performance, an advanced camera system, enhanced durability, the magic of MagSafe, and double the starting storag…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • C1X modem is up to 2x faster than C1 in iPhone 16e and matches the speed of iPhone Air

    80% confidence

  • iPad Air with M4 is up to 30 percent faster than iPad Air with M3

    80% confidence

  • T-Mobile has the Best Mobile Network in the U.S. based on analysis of Speedtest Intelligence data from 2H 2025

    80% confidence

  • C1X cellular modem offers up to 50 percent faster cellular data performance and up to 30 percent less modem energy usage than iPad Air with M3 for active cellular users

    80% confidence

  • T-Mobile families have saved over $3,700 versus AT&T and Verizon in the past 5 years based on real monthly bill analysis

    80% confidence

  • T-Mobile offers the Best Entertainment Bundle in Wireless

    80% confidence

  • Ceramic Shield 2 offers 3x better scratch resistance than the previous generation and reduced glare

    80% confidence

  • iPad Air with M4 is up to 2.3x faster than iPad Air with M1

    80% confidence

  • T-Mobile operates America's Best Network

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Oncology Data Season and Biotech Capital Allocation: ESMO Readouts, Ivonescimab PDUFA, and Diverging Corporate Moves
Late-2026 biotech is driven by a dense catalyst calendar. ESMO 2026 delivers data from ivonescimab, Enhertu, R-DXd and bemarituzumab, and the FDA has set a 14 Nov PDUFA date for the ivonescimab BLA. Capital allocation is diverging. Krystal Biotech authorized a $400M buyback while lowering FY2026 spend guidance and pushing milestones into 2027. Spago is moving to delist from Nasdaq First North. The facts are clinical and corporate events, not AI or fintech, so the finance angle is limited to capital markets (buybacks, guidance, delistings, regulatory timelines).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,996
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,996 facts checked against source5,552 source documents archived
Query this data → isubstrate.com